JP2024015087A - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- JP2024015087A JP2024015087A JP2023201066A JP2023201066A JP2024015087A JP 2024015087 A JP2024015087 A JP 2024015087A JP 2023201066 A JP2023201066 A JP 2023201066A JP 2023201066 A JP2023201066 A JP 2023201066A JP 2024015087 A JP2024015087 A JP 2024015087A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- oral composition
- endurance
- component
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 239000004475 Arginine Substances 0.000 claims abstract description 39
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229960003121 arginine Drugs 0.000 claims abstract description 39
- 239000000419 plant extract Substances 0.000 claims abstract description 34
- 229920002770 condensed tannin Polymers 0.000 claims abstract description 24
- 241000219428 Fagaceae Species 0.000 claims abstract description 23
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 22
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 13
- 229940009098 aspartate Drugs 0.000 claims abstract description 13
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 12
- 229960000310 isoleucine Drugs 0.000 claims abstract description 12
- 229960003136 leucine Drugs 0.000 claims abstract description 12
- 229960004295 valine Drugs 0.000 claims abstract description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 11
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 11
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004474 valine Substances 0.000 claims abstract description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 9
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 9
- 229960005261 aspartic acid Drugs 0.000 claims abstract description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 9
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims abstract description 8
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960002173 citrulline Drugs 0.000 claims abstract description 8
- 235000013477 citrulline Nutrition 0.000 claims abstract description 8
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 7
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 7
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 7
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960003104 ornithine Drugs 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 33
- 229940106587 pine bark extract Drugs 0.000 claims description 11
- 235000011471 Quercus robur Nutrition 0.000 claims description 10
- 240000009089 Quercus robur Species 0.000 claims description 10
- 235000020741 pine bark extract Nutrition 0.000 claims description 10
- 238000010586 diagram Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 38
- 235000009697 arginine Nutrition 0.000 description 35
- 235000002639 sodium chloride Nutrition 0.000 description 24
- 150000003839 salts Chemical class 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 235000013305 food Nutrition 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- -1 3,4,5-trihydroxyphenyl group Chemical group 0.000 description 10
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 10
- 239000000654 additive Substances 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 239000000049 pigment Substances 0.000 description 10
- 230000009183 running Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229920001968 ellagitannin Polymers 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000000112 Myalgia Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 208000013465 muscle pain Diseases 0.000 description 6
- 230000003387 muscular Effects 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 241001236212 Pinus pinaster Species 0.000 description 5
- 235000005105 Pinus pinaster Nutrition 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000036299 sexual function Effects 0.000 description 5
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 241000219492 Quercus Species 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 235000010204 pine bark Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000037078 sports performance Effects 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 229920001865 Castalagin Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical class OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920001958 Grandinin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 244000070406 Malus silvestris Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UDYKDZHZAKSYCO-WETOHNLWSA-N Vescalagin Natural products O=C1O[C@H]2[C@H](O)c3c(O)c(O)c(O)c(-c4c(O)c(O)c(O)c5-c6c(O)c(O)c(O)cc6C(=O)O[C@@H]6[C@H](OC(=O)c7c(c(O)c(O)c(O)c7)-c7c(O)c(O)c(O)cc7C(=O)OC6)[C@H]2OC(=O)c45)c13 UDYKDZHZAKSYCO-WETOHNLWSA-N 0.000 description 2
- SCGCYQONNCQISP-UHFFFAOYSA-N Vescalin Natural products OCC1OC(=O)c2cc(O)c(O)c(O)c2c3c(O)c(O)c(O)cc3C(=O)OC(C1O)C4OC(=O)c5cc(O)c(O)c(O)c5C4O SCGCYQONNCQISP-UHFFFAOYSA-N 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000000386 athletic effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- UDYKDZHZAKSYCO-CIBWSTISSA-N castalagin Chemical compound C([C@H]1OC(=O)C2=CC(O)=C(O)C(O)=C2C=2C(O)=C(O)C(O)=C(C=2C(=O)O2)C3=C(O)C(O)=C4O)OC(=O)C5=CC(O)=C(O)C(O)=C5C5=C(O)C(O)=C(O)C=C5C(=O)O[C@H]1[C@H]2[C@@H]1[C@@H](O)C4=C3C(=O)O1 UDYKDZHZAKSYCO-CIBWSTISSA-N 0.000 description 2
- FTFKAWWJGCCSJT-UHFFFAOYSA-N castalagin Natural products OC1OC2C(O)c3c(O)c(O)c(O)c(c13)c4c(O)c(O)c(O)c5c4C(=O)OC2C6OC(=O)c7cc(O)c(O)c(O)c7c8c(O)c(O)c(O)cc8C(=O)OCC6OC(=O)c9cc(O)c(O)c(O)c59 FTFKAWWJGCCSJT-UHFFFAOYSA-N 0.000 description 2
- ZVFDKYBWZMATCT-MVLAPQGRSA-N chembl506427 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)COC1(O)[C@H]1C(C(O)=C(O)C(O)=C2C3=C(O)C(O)=C4O)=C2C(=O)O[C@@H]1[C@@H]1[C@@H]2OC(=O)C5=CC(O)=C(O)C(O)=C5C5=C(O)C(O)=C(O)C=C5C(=O)OC[C@H]2OC(=O)C2=CC(O)=C(O)C(O)=C2C4=C3C(=O)O1 ZVFDKYBWZMATCT-MVLAPQGRSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Chemical class 0.000 description 2
- 229940127081 grandinin Drugs 0.000 description 2
- IHBQFOUFVYPLPE-UHFFFAOYSA-N grandinin Natural products OCC(O)C(O)C(O)C(=O)C1C2OC(O)c3c1c(O)c(O)c(O)c3c4c(O)c(O)c(O)c5c4C(=O)OC2C6OC(=O)c7cc(O)c(O)c(O)c7c8c(O)c(O)c(O)cc8C(=O)OCC6OC(=O)c9cc(O)c(O)c(O)c59 IHBQFOUFVYPLPE-UHFFFAOYSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000014666 liquid concentrate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical class OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- 235000018192 pine bark supplement Nutrition 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 229940106796 pycnogenol Drugs 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 230000007103 stamina Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- CEZCCHQBSQPRMU-LLIZZRELSA-L Allura red AC Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1\N=N\C1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-LLIZZRELSA-L 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 244000017106 Bixa orellana Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 229920001757 Castalin Polymers 0.000 description 1
- PPUHUWSVCUJGTD-UTSKMKSGSA-N Castalin Natural products O=C1O[C@H]2[C@H](O)c3c(O)c(O)c(O)c(-c4c(O)c(O)c(O)c5-c6c(O)c(O)c(O)cc6C(=O)O[C@@H](CO)[C@@H](O)[C@H]2OC(=O)c45)c13 PPUHUWSVCUJGTD-UTSKMKSGSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 239000004214 Fast Green FCF Substances 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical group OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YBHQCJILTOVLHD-YVMONPNESA-N Mirin Chemical compound S1C(N)=NC(=O)\C1=C\C1=CC=C(O)C=C1 YBHQCJILTOVLHD-YVMONPNESA-N 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 235000009137 Quercus alba Nutrition 0.000 description 1
- 244000274906 Quercus alba Species 0.000 description 1
- 240000008751 Quercus petraea Species 0.000 description 1
- 235000002913 Quercus petraea Nutrition 0.000 description 1
- 235000016977 Quercus suber Nutrition 0.000 description 1
- 240000008289 Quercus suber Species 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 239000009875 Robuvit Substances 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241001085768 Stereolepis gigas Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- OIQPTROHQCGFEF-QIKYXUGXSA-L Sunset Yellow FCF Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-QIKYXUGXSA-L 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000012741 allura red AC Nutrition 0.000 description 1
- 239000004191 allura red AC Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012665 annatto Nutrition 0.000 description 1
- 239000010362 annatto Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003403 betaine hydrochloride Drugs 0.000 description 1
- 229960002123 bethanechol chloride Drugs 0.000 description 1
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000004161 brilliant blue FCF Substances 0.000 description 1
- 229940055580 brilliant blue fcf Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 229960000678 carnitine chloride Drugs 0.000 description 1
- PPUHUWSVCUJGTD-UHFFFAOYSA-N castalin Chemical compound OC1C(CO)OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(O)C(C3=C(O)C(O)=C4O)=C2C(=O)OC1C1C(O)C4=C3C(=O)O1 PPUHUWSVCUJGTD-UHFFFAOYSA-N 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930002879 flavonoid pigment Natural products 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 229960003988 indigo carmine Drugs 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940048276 new coccine Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000012731 ponceau 4R Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000012751 sunset yellow FCF Nutrition 0.000 description 1
- 239000004173 sunset yellow FCF Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
【課題】本発明の目的は、持久力を向上させることができる経口組成物を提供することである。【解決手段】(A)プロアントシアニジンを含む植物抽出物、(B)ブナ科植物抽出物、(C)アルギニン、シトルリン、オルニチン、アスパラギン酸、アスパラギン酸塩及び/又はアスパラギン酸ジペプチドからなる群より選択されるアルギニン源、及び(D)バリン、ロイシン、及びイソロイシンからなる群より選択される分岐鎖アミノ酸を含む経口組成物は、持久力を向上させることができる。【選択図】なしAn object of the present invention is to provide an oral composition capable of improving endurance. [Solution] Selected from the group consisting of (A) a plant extract containing proanthocyanidins, (B) a Fagaceae plant extract, (C) arginine, citrulline, ornithine, aspartic acid, aspartate and/or aspartate dipeptide. An oral composition comprising a source of arginine and (D) a branched chain amino acid selected from the group consisting of valine, leucine, and isoleucine can improve endurance. [Selection diagram] None
Description
本発明は、持久力を向上させる経口組成物に関する。 The present invention relates to oral compositions that improve endurance.
プロアントシアニジンは、ポリフェノール類の一種で、フランス海岸松樹皮抽出物等に含まれる強力な抗酸化作用を有する物質である。プロアントシアニジンの生理活性作用としては、血中脂質改善効果、抗高血圧効果、血糖値上昇抑制効果、血管保護効果、ビタミンCの利用効率向上効果、血液流動性改善効果等が挙げられる。さらに、プロアントシアニジンによる生理活性作用を増強させるための処方が種々提案されており、例えば、特許文献1には、プロアントシアニジンに3,4,5-トリヒドロキシフェニル基を有するカテキン類を組み合わせることで、プロアントシアニジンが有する血中の脂質改善効果、脂質代謝改善効果、血糖値上昇抑制効果、抗高血圧効果、血流改善効果、美肌効果などの生理活性を顕著に増強することが記載されている。 Proanthocyanidin is a type of polyphenol and is a substance that has a strong antioxidant effect and is contained in French maritime pine bark extract. Physiologically active effects of proanthocyanidins include blood lipid improving effects, antihypertensive effects, blood sugar level increase suppressing effects, blood vessel protecting effects, vitamin C utilization efficiency improving effects, blood fluidity improving effects, and the like. Furthermore, various formulations have been proposed to enhance the physiologically active effects of proanthocyanidins. For example, Patent Document 1 suggests that by combining proanthocyanidins with catechins having a 3,4,5-trihydroxyphenyl group, It has been described that proanthocyanidins significantly enhance the physiological activities of proanthocyanidins, such as improving blood lipids, improving lipid metabolism, suppressing blood sugar rise, antihypertensive effects, improving blood flow, and beautifying the skin.
ブナ科植物抽出物は、エラジタンニンを含むことで知られている。エラジタンニンもポリフェノール類の一種であり、医薬や健康増進を目的とした利用が期待されている、例えば、特許文献2には、ブナ科の植物エキスから得られるエラジタンニンリッチな抽出物組成物が、男女の性的適応度または性的機能の改善方法、男性の精力増強方法、男女の性的脈管系の性的機能不全および健康の治療方法または予防方法において使用されることが記載されている。また、特許文献3には、ブナ科の植物エキスから得られるエラジタンニンリッチな抽出物からなる組成物が、被験者における気分を改善し、ストレスを低下させ、エネルギーを向上させて、疲労、不安および睡眠障害の予防方法または治療方法において使用されることが記載されている。 Fagaceae plant extracts are known to contain ellagitannins. Ellagitannin is also a type of polyphenol, and is expected to be used for medicine and health promotion purposes. For example, Patent Document 2 describes an extract composition rich in ellagitannin obtained from a Fagaceae plant extract. , described for use in methods for improving sexual fitness or sexual function in men and women, methods for enhancing male virility, methods for treating or preventing sexual dysfunction and health of the sexual vascular system in men and women. There is. Furthermore, Patent Document 3 discloses that a composition comprising an ellagitannin-rich extract obtained from a plant extract of the Fagaceae family improves mood, lowers stress, and improves energy in test subjects, reducing fatigue and anxiety. and use in methods for preventing or treating sleep disorders.
アルギニンは、一酸化窒素(NO)合成酵素の直接的な基質となるアミノ酸として、肝臓における尿素回路の中間体として、及び成長ホルモン分泌作用を有する物質として知られている。アルギニンの生理活性作用としては、血管拡張、血圧上昇抑、性的機能改善、筋肉合成、創傷治癒、アンモニア解毒、免疫賦活、インスリン分泌、ポリアミン合成作用が挙げられる。さらに、アルギニンによる生理活性作用をより有効に得るための処方が提案されており、特許文献4には、シトルリンまたはその塩およびアルギニンまたはその塩を有効成分として含有する、即効性血中アルギニン濃度上昇型経口剤が、経口摂取後速やかに血中のアルギニン濃度を上昇できることが記載されている。 Arginine is known as an amino acid that is a direct substrate of nitric oxide (NO) synthase, as an intermediate in the urea cycle in the liver, and as a substance that has a growth hormone secreting effect. Physiologically active effects of arginine include vasodilation, suppression of blood pressure increase, sexual function improvement, muscle synthesis, wound healing, ammonia detoxification, immune activation, insulin secretion, and polyamine synthesis effects. Furthermore, a formulation for more effectively obtaining the physiologically active effect of arginine has been proposed, and Patent Document 4 discloses an immediate-acting formulation for increasing blood arginine concentration containing citrulline or its salt and arginine or its salt as active ingredients. It has been described that the arginine concentration in the blood can be increased immediately after oral intake.
バリン、ロイシン、イソロイシンは、分岐鎖アミノ酸(BCAA)と呼ばれ、その3種アミノ酸の混合物には筋肉疲労回復効果があることが知られている。また、特許文献5には、それぞれ所定量の、ロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質分解物のみを含有し、且つ1日1回運動直後に経口投与される、運動後の筋肉蛋白分解の持続的抑制剤によって、筋肉疲労回復の効果を持続的に得ることができることが記載されている。 Valine, leucine, and isoleucine are called branched chain amino acids (BCAAs), and a mixture of these three amino acids is known to have the effect of recovering from muscle fatigue. Further, Patent Document 5 discloses a post-exercise muscle protein decomposition product containing only predetermined amounts of leucine, isoleucine, valine, glutamine, and whey protein decomposition products, and which is orally administered once a day immediately after exercise. It is described that the effect of muscle fatigue recovery can be obtained continuously by using a long-lasting inhibitor.
このように、プロアントシアニジンを含む植物抽出物、ブナ科植物抽出物、アルギニン、及び分岐鎖アミノ酸は、様々な生理活性作用を利用した経口組成物に用いられている。これらの成分による生理活性は多種多様であり、それに応じて経口組成物の用途も多種多様である。そして、多くの用途への有効性が知られているにも関わらず、これらの成分のすべてにおいて共通又は関連する用途は無い。このため、これらの成分の全てを含む経口組成物は知られていない。 As described above, plant extracts containing proanthocyanidins, Fagaceae plant extracts, arginine, and branched chain amino acids are used in oral compositions that utilize various physiologically active actions. The physiological activities of these ingredients are diverse, and the uses of oral compositions are correspondingly diverse. And despite their known effectiveness in many applications, there are no common or related uses for all of these ingredients. For this reason, oral compositions containing all of these components are not known.
また、上記の成分は多くの生理活性が知られているにも関わらず、持久力を向上させる作用については一切知られていない。持久力には、心肺持久力ともいわれる全身持久力が挙げられ、全身持久力は、長時間にわたって全身を動かせる能力をいう。全身持久力は、例えば、長距離ランニング、水泳、自転車といった持久系スポーツのパフォーマンスに代表される。 Furthermore, although the above-mentioned components are known to have many physiological activities, nothing is known about their ability to improve endurance. Endurance includes whole body endurance, also known as cardiopulmonary endurance, which refers to the ability to move the whole body for a long period of time. Whole-body endurance is exemplified by performance in endurance sports such as long-distance running, swimming, and cycling.
そこで、本発明は、持久力を向上させることができる経口組成物を提供することを目的とする。 Therefore, an object of the present invention is to provide an oral composition that can improve endurance.
本発明者らは鋭意検討を行ったところ、プロアントシアニジンを含む植物抽出物、ブナ科植物抽出物、及びアルギニン源(アルギニン及び体内でアルギニンに転換される成分を含む)を組み合わせた経口組成物が、驚くべきことに、これまで知られていなかった持久力向上作用を発揮することを見出した。更に驚くべきことに、プロアントシアニジンを含む植物抽出物、ブナ科植物抽出物、及びアルギニン源(アルギニン及び体内でアルギニンに転換される成分を含む)を組み合わせた経口組成物に、分岐鎖アミノ酸を組み合わせることで、持久力向上作用が更に向上することも見出した。本発明は、かかる知見に基づいて更に検討を重ねることにより完成したものである。 The present inventors conducted extensive research and found that an oral composition that combines a plant extract containing proanthocyanidins, a Fagaceae plant extract, and an arginine source (including arginine and a component that is converted to arginine in the body) was found. Surprisingly, they discovered that it exerts a hitherto unknown effect on improving endurance. Even more surprisingly, an oral composition that combines a plant extract containing proanthocyanidins, a Fagaceae plant extract, and a source of arginine (including arginine and a component that is converted to arginine in the body) combines branched chain amino acids. It has also been found that the endurance-improving effect can be further improved by doing so. The present invention was completed through further studies based on this knowledge.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項1. (A)プロアントシアニジンを含む植物抽出物、(B)ブナ科植物抽出物、(C)アルギニン、シトルリン、オルニチン、アスパラギン酸、アスパラギン酸塩及び/又はアスパラギン酸ジペプチドからなる群より選択されるアルギニン源、並びに、(D)バリン、ロイシン、及びイソロイシンからなる群より選択される分岐鎖アミノ酸を含む、経口組成物。
項2. 前記(A)成分が松樹皮抽出物である、項1に記載の経口組成物。
項3. 前記(B)成分が、ヨーロッパナラ抽出物である、項1又は2に記載の経口組成物。
項4. 前記(A)成分1重量部に対し、前記(B)成分が0.15重量部以上含まれる、項1~3のいずれかに記載の経口組成物。
項5. 持久力の向上に用いられる、項1~4のいずれかに記載の経口組成物。
項6. 前記持久力が、全身持久力である、項5に記載の経口組成物。
項7. (A)プロアントシアニジンを含む植物抽出物、(B)ブナ科植物抽出物、並びに、(C)アルギニン、シトルリン、オルニチン、アスパラギン酸、アスパラギン酸塩及び/又はアスパラギン酸ジペプチドからなる群より選択されるアルギニン源を含む、持久力の向上に用いられる経口組成物。
That is, the present invention provides the inventions of the following aspects.
Item 1. (A) a plant extract containing proanthocyanidins, (B) a Fagaceae plant extract, (C) an arginine source selected from the group consisting of arginine, citrulline, ornithine, aspartic acid, aspartate and/or aspartate dipeptide , and (D) a branched chain amino acid selected from the group consisting of valine, leucine, and isoleucine.
Item 2. Item 2. The oral composition according to item 1, wherein the component (A) is a pine bark extract.
Item 3. Item 3. The oral composition according to item 1 or 2, wherein the component (B) is a European oak extract.
Item 4. Item 4. The oral composition according to any one of Items 1 to 3, wherein the component (B) is contained in an amount of 0.15 parts by weight or more per 1 part by weight of the component (A).
Item 5. Item 5. The oral composition according to any one of Items 1 to 4, which is used for improving endurance.
Item 6. Item 6. The oral composition according to Item 5, wherein the endurance is whole body endurance.
Section 7. (A) a plant extract containing proanthocyanidins, (B) a Fagaceae plant extract, and (C) selected from the group consisting of arginine, citrulline, ornithine, aspartic acid, aspartate and/or aspartate dipeptide. An oral composition used to improve endurance performance, comprising a source of arginine.
本発明の経口組成物によれば、持久力を向上させることができる。従って、例えば持久系スポーツのパフォーマンスを向上させたり、運動中又は運動終了時において生じる筋肉不快感を低減させたりすることができる。 According to the oral composition of the present invention, endurance can be improved. Therefore, for example, performance in endurance sports can be improved, and muscle discomfort that occurs during or at the end of exercise can be reduced.
本発明の経口組成物は、(A)プロアントシアニジンを含む植物抽出物(以下において、「(A)成分」とも記載する)、(B)ブナ科植物抽出物(以下において、「(B)成分」とも記載する)、(C)アルギニン、シトルリン、オルニチン、アスパラギン酸、アスパラギン酸塩及び/又はアスパラギン酸ジペプチドからなる群より選択されるアルギニン源(以下において、「(C)成分」とも記載する)、及び(D)バリン、ロイシン、及びイソロイシンからなる群より選択される分岐鎖アミノ酸(以下において、「(D)成分」とも記載する)を含むことを特徴とする。以下、本発明の経口組成物について詳述する。 The oral composition of the present invention contains (A) a plant extract containing proanthocyanidins (hereinafter also referred to as "(A) component"), (B) a Fagaceae plant extract (hereinafter referred to as "(B) component"). ), (C) an arginine source selected from the group consisting of arginine, citrulline, ornithine, aspartic acid, aspartate and/or aspartic acid dipeptide (hereinafter also referred to as "component (C)") , and (D) a branched chain amino acid selected from the group consisting of valine, leucine, and isoleucine (hereinafter also referred to as "component (D)"). The oral composition of the present invention will be described in detail below.
(A)プロアントシアニジンを含む植物抽出物
本発明の経口組成物は、(A)成分としてプロアントシアニジンを含む植物抽出物を含む。プロアントシアニジンは、ポリフェノール類の一種であり、フラバノール骨格を有する縮合型タンニンである。プロアントシアニジンは、血中脂質改善効果、抗高血圧効果、血糖値上昇抑制効果、血管保護効果、ビタミンCの利用効率向上効果、血液流動性改善効果等を有する公知の成分である。
(A) Plant extract containing proanthocyanidins The oral composition of the present invention contains a plant extract containing proanthocyanidins as component (A). Proanthocyanidins are a type of polyphenols and are condensed tannins having a flavanol skeleton. Proanthocyanidins are known components that have effects such as improving blood lipids, antihypertensive effects, suppressing blood sugar level rise, protecting blood vessels, improving vitamin C utilization efficiency, and improving blood fluidity.
プロアントシアニジンを含む植物抽出物の由来元となる植物としては特に限定されないが、例えば、松樹皮、ブドウ種子、ブドウ果皮、イチョウ葉、落花生種皮、カカオ豆、タマリンド、スグリ(クロフサスグリ)、アーモンド、リンゴ、ラズベリー、クランベリー、ブルーベリー、茶葉等の抽出物が挙げられる。これらの中でも、より好ましい持久力向上効果を得る観点から、好ましくは松樹皮が挙げられる。松樹皮の由来元となる松としては、例えば、フランス海岸松(Pinus pinaster)、フィンランド産松、ニュージーランド産松が挙げられる。これらの中でも、より一層好ましい持久力向上効果を得る観点から、好ましくはフランス海岸松が挙げられる。 Plants from which plant extracts containing proanthocyanidins are derived are not particularly limited, but include, for example, pine bark, grape seeds, grape skin, ginkgo biloba leaves, peanut seed coats, cacao beans, tamarind, currants (black currants), almonds, and apples. , raspberry, cranberry, blueberry, tea leaf, and other extracts. Among these, pine bark is preferred from the viewpoint of obtaining a more preferable effect of improving endurance. Examples of pines from which pine bark is derived include French maritime pine (Pinus pinaster), Finnish pine, and New Zealand pine. Among these, French maritime pine is preferred from the viewpoint of obtaining a more favorable effect of improving endurance.
(A)成分としては、これらの植物の抽出物から、1種単独で用いてもよく、2種以上を組み合わせて用いてもよい。また、これらの植物の抽出物としては、公知の抽出方法により自ら調製したものを用いてもよいし、市販品を用いてもよい。フランス海岸松樹皮抽出物の市販品としては、例えば商品名「ピクノジェノール」(スイス、ホファー・リサーチ社製)、商品名「フラバンジェノール」((株)東洋新薬販売)が挙げられる。フィンランド産松樹皮抽出物の市販品としては、例えば商品名「フィンジェノール」が挙げられる。ニュージーランド産松樹皮抽出物の市販品としては、例えば商品名「エンゾジノール」が挙げられる。 As the component (A), one type of these plant extracts may be used alone, or two or more types may be used in combination. Moreover, as extracts of these plants, those prepared by oneself by a known extraction method may be used, or commercially available products may be used. Commercially available French maritime pine bark extracts include, for example, the trade name "Pycnogenol" (manufactured by Hofer Research, Switzerland) and the trade name "Flavangenol" (Toyo Shinyaku Sales Co., Ltd.). A commercially available product of Finnish pine bark extract includes, for example, the trade name "Fingenol". A commercially available New Zealand pine bark extract includes, for example, the trade name "Enzogenol."
プロアントシアニジンを含む植物抽出物としては、具体的には、搾汁、溶媒抽出物、溶媒抽出物のプロアントシアニジンを含む分画物等が挙げられる。また、抽出物の具体的態様としては、非濃縮エキス(濃縮処理されていないもの)、軟エキス(つまり液状濃縮物)及びエキス末(つまり乾燥物)が挙げられる。また、濃縮率としては、抽出物重量に対する原料乾燥重量の比率(原料乾燥重量/抽出物重量)が、500~1500倍、好ましくは800~1200倍が挙げられる。 Specific examples of plant extracts containing proanthocyanidins include squeezed juice, solvent extracts, fractions of solvent extracts containing proanthocyanidins, and the like. Further, specific embodiments of the extract include non-concentrated extract (not subjected to concentration treatment), soft extract (that is, liquid concentrate), and extract powder (that is, dried product). Further, as the concentration ratio, the ratio of the dry weight of raw materials to the weight of the extract (dry weight of raw materials/weight of extract) is 500 to 1500 times, preferably 800 to 1200 times.
プロアントシアニジンを含む植物抽出物を得るための抽出溶媒としては、水、有機溶媒(メタノール、エタノール、n-プロパノール、イソプロパノール、n-ブタノール等の炭素数1~4の低級アルコール;プロピレングリコール、1,3-ブチレングリコール等の多価アルコール;アセトン等のケトン類;ジエチルエーテル、ジオキサン、アセトニトリル、酢酸エチルエステル等のエステル類;キシレン、ベンゼン、クロロホルム等)、これらの混合物が挙げられる。これらの抽出溶媒は1種単独で用いてもよく、2種以上を組み合わせて用いてもよい。これらの抽出溶媒の中でも、好ましくは、水、低級アルコール、これらの混合物が挙げられ、より好ましくは、含水低級アルコールが挙げられ、さらに好ましくは、含水エタノールが挙げられる。 Extraction solvents for obtaining plant extracts containing proanthocyanidins include water, organic solvents (lower alcohols with 1 to 4 carbon atoms such as methanol, ethanol, n-propanol, isopropanol, and n-butanol; propylene glycol, 1, Examples include polyhydric alcohols such as 3-butylene glycol; ketones such as acetone; esters such as diethyl ether, dioxane, acetonitrile, and ethyl acetate; xylene, benzene, chloroform, etc.), and mixtures thereof. These extraction solvents may be used alone or in combination of two or more. Among these extraction solvents, water, lower alcohols, and mixtures thereof are preferred, water-containing lower alcohols are more preferred, and water-containing ethanol is even more preferred.
本発明の経口組成物において、(A)~(D)成分の総量100重量%に対する(A)成分の含有比率については、付与すべき効能に応じ適宜設定すればよく、特に限定されないが、乾燥重量換算で、例えば、0.2~55重量%が挙げられる。より好ましい持久力向上効果を得る観点から、(A)成分の含有比率としては、好ましくは0.5~55重量%、より好ましくは0.9~55重量%が挙げられる。また、本発明の経口組成物は持久力向上効果に優れているため、(A)成分が少量であっても効果的に持久力を向上させることができる。この観点から、(A)成分の含有比率の好ましい例として、0.9~17重量%、好ましくは0.9~10重量%、より好ましくは0.9~5重量%、さらにより好ましくは0.9~3重量%、一層好ましくは0.9~2重量%が挙げられる。 In the oral composition of the present invention, the content ratio of component (A) to 100% by weight of the total amount of components (A) to (D) may be appropriately set depending on the efficacy to be imparted, and is not particularly limited. In terms of weight, for example, 0.2 to 55% by weight. From the viewpoint of obtaining a more preferable endurance-improving effect, the content ratio of component (A) is preferably 0.5 to 55% by weight, more preferably 0.9 to 55% by weight. Moreover, since the oral composition of the present invention is excellent in the effect of improving endurance, even if component (A) is contained in a small amount, endurance can be effectively improved. From this point of view, preferred examples of the content ratio of component (A) are 0.9 to 17% by weight, preferably 0.9 to 10% by weight, more preferably 0.9 to 5% by weight, even more preferably 0. .9 to 3% by weight, more preferably 0.9 to 2% by weight.
本発明の経口組成物において、(A)~(C)成分の総量100重量%に対する(A)成分の含有比率については、付与すべき効能に応じ適宜設定すればよく、特に限定されないが、乾燥重量換算で、例えば、0.5~71重量%が挙げられる。より好ましい持久力向上効果を得る観点から、(A)成分の含有比率としては、好ましくは1~71重量%、より好ましくは4~71重量%が挙げられる。また、本発明の経口組成物は持久力向上効果に優れているため、(A)成分が少量であっても効果的に持久力を向上させることができる。この観点から、(A)成分の含有比率の好ましい例として、4~50重量%、好ましくは4~20重量%、より好ましくは4~10重量%、さらに好ましくは4~9重量%、一層好ましくは4~7重量%が挙げられる。 In the oral composition of the present invention, the content ratio of component (A) to 100% by weight of the total amount of components (A) to (C) may be appropriately set depending on the efficacy to be imparted, and is not particularly limited. In terms of weight, for example, 0.5 to 71% by weight. From the viewpoint of obtaining a more preferable endurance-improving effect, the content ratio of component (A) is preferably 1 to 71% by weight, more preferably 4 to 71% by weight. Moreover, since the oral composition of the present invention is excellent in the effect of improving endurance, even if component (A) is contained in a small amount, endurance can be effectively improved. From this point of view, preferred examples of the content ratio of component (A) are 4 to 50% by weight, preferably 4 to 20% by weight, more preferably 4 to 10% by weight, still more preferably 4 to 9% by weight, and even more preferably is 4 to 7% by weight.
(B)ブナ科植物抽出物
本発明の経口組成物は、(B)成分としてブナ科植物抽出物を含む。ブナ科植物抽出物はポリフェノール類の一種であるエラジタンニンを含む。ブナ科植物抽出物は、男女の性的適応度または性的機能の改善、男性の精力増強、男女の性的脈管系の性的機能改善又は低下予防効果、気分改善、ストレス低下、エネルギー向上、並びに、疲労、不安および睡眠障害の予防又は治療効果等を有する公知の成分である。
(B) Fagaceae Plant Extract The oral composition of the present invention contains a Fagaceae plant extract as the component (B). Fagaceae plant extract contains ellagitannin, which is a type of polyphenol. Fagaceae plant extract improves sexual fitness or sexual function in men and women, enhances male virility, improves sexual function or prevents decline in sexual vascular system in men and women, improves mood, reduces stress, and improves energy. , and is a known ingredient that has preventive or therapeutic effects on fatigue, anxiety, and sleep disorders.
エラジタンニンは、様々な加水分解性タンニンを含有しており、エラジタンニンに含まれる成分としては、ロブリン、ベスカラギン、カスタラギン、グランジニン、ベスカリン、カスタリン等が挙げられ、好ましくは、ロブリン、べスカラギン、カスタラギン、グランジニンが挙げられる。また、ロブリンには、ロブリンA、ロブリンB、ロブリンC、ロブリンD、ロブリンEより選択される1種又は複数種、好ましくはロブリンA、ロブリンB、ロブリンC、ロブリンD、及びロブリンEの全てが含まれる。 Ellagitannins contain various hydrolyzable tannins, and components contained in ellagitannins include lobulin, vescalagin, castaragin, grandinin, vescalin, castalin, etc., and preferably, robulin, vescalagin, castaragin, grandinin. can be mentioned. Further, Robulin includes one or more types selected from Robulin A, Robulin B, Robulin C, Robulin D, and Robulin E, preferably all of Robulin A, Robulin B, Robulin C, Robulin D, and Robulin E. included.
ブナ科植物抽出物には、エラジタンニンの他、フェノール酸を含んでいることが好ましい。フェノール酸としては、没食子酸、エラグ酸が挙げられる。 The Fagaceae plant extract preferably contains phenolic acids in addition to ellagitannins. Examples of phenolic acids include gallic acid and ellagic acid.
ブナ科植物抽出物の由来元となるブナ科植物としては特に限定されないが、例えば、オーク、コルクガシ等が挙げられる。より好ましい持久力向上効果を得る観点から、好ましくはオークが挙げられる。オークとしては、ヨーロッパナラ(Quercus robur)、フユナラ(Quercus petraea)、アルバオーク(Quercus alba)等が挙げられ、より一層好まし
い持久力向上効果を得る観点から、好ましくはヨーロッパナラが挙げられる。これらのブナ科植物としては、国有林事務局(National Forest Office)の管轄下の木を、樹液が落ちるときの10月~4月に伐採したものを用いることが好ましい。
The Fagaceae plant from which the Fagaceae plant extract is derived is not particularly limited, but includes, for example, oak, cork oak, and the like. From the viewpoint of obtaining a more favorable stamina-improving effect, oak is preferably used. Examples of the oak include Quercus robur, Quercus petraea, and Quercus alba, and from the viewpoint of obtaining a more favorable effect of improving endurance, European oak is preferred. As these Fagaceae plants, it is preferable to use trees under the jurisdiction of the National Forest Office that are felled from October to April, when the sap falls.
(B)成分としては、これらのブナ科植物の抽出物から、1種単独で用いてもよく、2種以上を組み合わせて用いてもよい。また、これらのブナ科植物の抽出物としては、公知の抽出方法により自ら調製したものを用いてもよいし、市販品を用いてもよい。ヨーロッパナラ抽出物の市販品としては、例えば商品名「ロブビット」(スイス、ホファー・リサーチ社製)が挙げられる。 As the component (B), one type of extracts of these Fagaceae plants may be used alone, or two or more types may be used in combination. Moreover, as extracts of these Fagaceae plants, those prepared by oneself by a known extraction method may be used, or commercially available products may be used. Commercially available European oak extracts include, for example, the trade name "Robvit" (manufactured by Hofer Research, Switzerland).
ブナ科植物抽出物としては、具体的には、搾汁、溶媒抽出物、溶媒抽出物のエラジタンニンを含む分画物等が挙げられる。また、抽出物の具体的態様としては、非濃縮エキス(濃縮処理されていないもの)、軟エキス(つまり液状濃縮物)及びエキス末(つまり乾燥物)が挙げられる。また、濃縮率としては、抽出物重量に対する原料乾燥重量の比率(原料乾燥重量/抽出物重量)が、30~70倍、好ましくは40~60倍が挙げられる。 Specific examples of Fagaceae plant extracts include squeezed juice, solvent extracts, and fractions of solvent extracts containing ellagitannins. Further, specific embodiments of the extract include non-concentrated extract (not subjected to concentration treatment), soft extract (that is, liquid concentrate), and extract powder (that is, dried product). Further, as for the concentration ratio, the ratio of the dry weight of the raw material to the weight of the extract (dry weight of the raw material/weight of the extract) is 30 to 70 times, preferably 40 to 60 times.
ブナ科植物抽出物を得るための抽出溶媒としては、水、有機溶媒(メタノール、エタノール、n-プロパノール、イソプロパノール、n-ブタノール等の炭素数1~4の低級アルコール;プロピレングリコール、1,3-ブチレングリコール等の多価アルコール;アセトン等のケトン類;ジエチルエーテル、ジオキサン、アセトニトリル、酢酸エチルエステル等のエステル類;キシレン、ベンゼン、クロロホルム等)、これらの混合物が挙げられる。これらの抽出溶媒は1種単独で用いてもよく、2種以上を組み合わせて用いてもよい。これらの抽出溶媒の中でも、好ましくは、好ましくは、水、低級アルコール、これらの混合物が挙げられ、より好ましくは、水が挙げられる。 Extraction solvents for obtaining Fagaceae plant extracts include water, organic solvents (lower alcohols with 1 to 4 carbon atoms such as methanol, ethanol, n-propanol, isopropanol, and n-butanol; propylene glycol, 1,3- Examples include polyhydric alcohols such as butylene glycol; ketones such as acetone; esters such as diethyl ether, dioxane, acetonitrile, and acetic acid ethyl ester; xylene, benzene, chloroform, etc.), and mixtures thereof. These extraction solvents may be used alone or in combination of two or more. Among these extraction solvents, water, lower alcohols, and mixtures thereof are preferably used, and water is more preferably used.
本発明の経口組成物において、(A)~(D)成分の総量100重量%に対する(B)成分の含有比率については、付与すべき効能に応じ適宜設定すればよく、特に限定されないが、乾燥重量換算で、例えば、0.02~10重量%が挙げられる。より好ましい持久力向上効果を得る観点から、(B)成分の含有比率としては、好ましくは0.02~9重量%、より好ましくは0.08~9重量%、さらに好ましくは0.1~9重量%、一層好ましくは0.15~9重量%が挙げられる。また、(B)成分の含有比率のさらなる例としては、0.08~2重量%、0.08~1重量%、0.08~0.8重量%、又は0.08~0.3重量%が挙げられる。 In the oral composition of the present invention, the content ratio of component (B) to 100% by weight of the total amount of components (A) to (D) may be appropriately set depending on the efficacy to be imparted, and is not particularly limited. In terms of weight, for example, 0.02 to 10% by weight. From the viewpoint of obtaining a more preferable endurance improvement effect, the content ratio of component (B) is preferably 0.02 to 9% by weight, more preferably 0.08 to 9% by weight, and even more preferably 0.1 to 9% by weight. % by weight, more preferably from 0.15 to 9% by weight. Furthermore, further examples of the content ratio of component (B) include 0.08 to 2% by weight, 0.08 to 1% by weight, 0.08 to 0.8% by weight, or 0.08 to 0.3% by weight. % is mentioned.
本発明の経口組成物において、(A)~(C)成分の総量100重量%に対する(B)成分の含有比率については、付与すべき効能に応じ適宜設定すればよく、特に限定されないが、乾燥重量換算で、例えば、0.04~20重量%が挙げられる。より好ましい持久力向上効果を得る観点から、(B)成分の含有比率としては、好ましくは0.04~16重量%、より好ましくは0.4~16重量%、さらに好ましくは0.5~16重量%、一層好ましくは0.6~16重量%、より一層好ましくは0.7~16重量%、特に好ましくは0.75~16重量%が挙げられる。また、(B)成分の含有比率のさらなる例としては、0.4~10重量%、0.4~5重量%、0.4~1重量%、又は0.4~0.9重量%が挙げられる。 In the oral composition of the present invention, the content ratio of component (B) to 100% by weight of the total amount of components (A) to (C) may be appropriately set depending on the efficacy to be imparted, and is not particularly limited. In terms of weight, for example, 0.04 to 20% by weight. From the viewpoint of obtaining a more preferable endurance improvement effect, the content ratio of component (B) is preferably 0.04 to 16% by weight, more preferably 0.4 to 16% by weight, and even more preferably 0.5 to 16% by weight. % by weight, more preferably from 0.6 to 16% by weight, even more preferably from 0.7 to 16% by weight, particularly preferably from 0.75 to 16% by weight. Furthermore, further examples of the content ratio of component (B) include 0.4 to 10% by weight, 0.4 to 5% by weight, 0.4 to 1% by weight, or 0.4 to 0.9% by weight. Can be mentioned.
本発明の経口組成物において、(A)成分と(B)成分との比率については、上記各成分の含有量により決定されるが、好ましくは、(A)成分1重量部に対する(B)成分の比率として、0.002重量部以上、好ましくは0.004重量部以上、より好ましくは0.008重量部以上、さらに好ましくは0.04重量部以上、一層好ましくは0.08重量部以上、より一層好ましくは0.13重量部以上、特に好ましくは0.15重量部以上、最も好ましくは0.16重量部以上が挙げられる。当該(B)成分の比率の範囲の上限としては、例えば、3.5重量部以下、3.3重量部以下、2重量部以下、1重量部以下、0.5重量部以下、又は0.3重量部以下が挙げられる。 In the oral composition of the present invention, the ratio of component (A) to component (B) is determined by the content of each of the above components, but preferably component (B) per 1 part by weight of component (A). as a ratio of 0.002 parts by weight or more, preferably 0.004 parts by weight or more, more preferably 0.008 parts by weight or more, still more preferably 0.04 parts by weight or more, even more preferably 0.08 parts by weight or more, It is even more preferably 0.13 parts by weight or more, particularly preferably 0.15 parts by weight or more, and most preferably 0.16 parts by weight or more. The upper limit of the range of the ratio of the component (B) is, for example, 3.5 parts by weight or less, 3.3 parts by weight or less, 2 parts by weight or less, 1 part by weight or less, 0.5 parts by weight or less, or 0.5 parts by weight or less. Examples include 3 parts by weight or less.
(C)アルギニン源
本発明の経口組成物は、(C)成分としてアルギニン、シトルリン、オルニチン、アスパラギン酸、アスパラギン酸塩及び/又はアスパラギン酸ジペプチドからなる群より選択されるアルギニン源を含む。
(C) Arginine source The oral composition of the present invention contains, as component (C), an arginine source selected from the group consisting of arginine, citrulline, ornithine, aspartic acid, aspartate and/or aspartate dipeptide.
アルギニンは、血管拡張、血圧上昇抑、性的機能改善、筋肉合成、創傷治癒、アンモニア解毒、免疫賦活、インスリン分泌、ポリアミン合成作用を有する公知の成分である。また、シトルリン、オルニチン、アスパラギン酸、アスパラギン酸塩及び/又はアスパラギン酸ジペプチドは、アルギニンに生合成されるアルギニン前駆体であり、経口摂取することによって体内でアルギニンに変換され、血中のアルギニンレベルを効率良く上昇させることができる。 Arginine is a known component that has vasodilation, suppression of blood pressure increase, sexual function improvement, muscle synthesis, wound healing, ammonia detoxification, immunostimulation, insulin secretion, and polyamine synthesis effects. In addition, citrulline, ornithine, aspartic acid, aspartate and/or aspartate dipeptide are arginine precursors that are biosynthesized to arginine, and when ingested orally, they are converted to arginine in the body and reduce the arginine level in the blood. It can be raised efficiently.
アスパラギン酸塩としては、酸付加塩、金属塩、アンモニウム塩、有機アミン付加塩、アミノ酸付加塩等が挙げられる。酸付加塩としては、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩、酢酸塩、マレイン酸塩、フマル酸塩、クエン酸塩、リンゴ酸塩、乳酸塩、α-ケトグルタル酸塩、グルコン酸塩、カプリル酸塩等の有機酸塩が挙げられる。金属塩としては、ナトリウム塩、カリウム塩等のアルカリ金属塩、マグネシウム塩、カルシウム塩等のアルカリ土類金属塩、アルミニウム塩、亜鉛塩等が挙げられる。アンモニウム塩としては、アンモニウム、テトラメチルアンモニウム等の塩が挙げられる。有機アミン付加塩としては、モルホリン、ピペリジン等の塩が挙げられる。アミノ酸付加塩としては、グリシン、フェニルアラニン、リジン、アスパラギン酸、グルタミン酸等の塩が挙げられる。 Aspartates include acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts, and the like. Acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, acetate, maleate, fumarate, citrate, malate, lactate, α-ketoglutarate. , gluconate, caprylate, and other organic acid salts. Examples of metal salts include alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as magnesium salts and calcium salts, aluminum salts, zinc salts, and the like. Examples of ammonium salts include salts such as ammonium and tetramethylammonium. Examples of organic amine addition salts include salts of morpholine, piperidine, and the like. Examples of amino acid addition salts include salts of glycine, phenylalanine, lysine, aspartic acid, glutamic acid, and the like.
(C)成分は、L-体、D-体およびDL-体のいずれであってもよいが、好ましくはL-体である。 Component (C) may be any of the L-form, D-form and DL-form, but preferably the L-form.
これらのアルギニン源は、食品添加物、食品素材などとして市販されており、本発明の口腔用組成物においては、市販のアルギニン源をいずれも利用することができる。 These arginine sources are commercially available as food additives, food materials, etc., and any commercially available arginine sources can be used in the oral composition of the present invention.
(C)成分としては、上述のアルギニン源から、1種単独で用いてもよく、2種以上を組み合わせて用いてもよい。 As component (C), one type from the above-mentioned arginine sources may be used alone, or two or more types may be used in combination.
本発明の経口組成物において、(A)~(D)成分の総量100重量%に対する(C)成分の含有比率については、付与すべき効能に応じ適宜設定すればよく、特に限定されないが、乾燥重量換算で、例えば、5~95重量%が挙げられる。より好ましい持久力向上効果を得る観点から、(C)成分の含有比率としては、好ましくは5~91重量%、より好ましくは10~91重量%、さらに好ましくは15~91重量%、一層好ましくは19~91重量%が挙げられる。また、(C)成分の含有比率のさらなる例としては、19~70重量%、19~50重量%、19~30重量%、又は19~25重量%が挙げられる。 In the oral composition of the present invention, the content ratio of component (C) to 100% by weight of the total amount of components (A) to (D) may be appropriately set depending on the efficacy to be imparted, and is not particularly limited. In terms of weight, for example, 5 to 95% by weight. From the viewpoint of obtaining a more preferable endurance improvement effect, the content ratio of component (C) is preferably 5 to 91% by weight, more preferably 10 to 91% by weight, even more preferably 15 to 91% by weight, and even more preferably Examples include 19 to 91% by weight. Furthermore, further examples of the content ratio of component (C) include 19 to 70% by weight, 19 to 50% by weight, 19 to 30% by weight, or 19 to 25% by weight.
本発明の経口組成物において、(A)~(C)成分の総量100重量%に対する(C)成分の含有比率については、付与すべき効能に応じ適宜設定すればよく、特に限定されないが、乾燥重量換算で、例えば、27~99.5重量%が挙げられる。より好ましい持久力向上効果を得る観点から、(C)成分の含有比率としては、好ましくは27~99.4重量%、より好ましくは29~99.4重量%、さらに好ましくは40~99.4重量%、一層好ましくは80~99.4重量%、より一層好ましくは90~99.4重量%が挙げられる。また、(C)成分の含有比率のさらなる例としては、90~97重量%が挙げられる。 In the oral composition of the present invention, the content ratio of component (C) to 100% by weight of the total amount of components (A) to (C) may be appropriately set depending on the efficacy to be imparted, and is not particularly limited. In terms of weight, for example, 27 to 99.5% by weight. From the viewpoint of obtaining a more preferable endurance improvement effect, the content ratio of component (C) is preferably 27 to 99.4% by weight, more preferably 29 to 99.4% by weight, and even more preferably 40 to 99.4% by weight. % by weight, more preferably 80-99.4% by weight, even more preferably 90-99.4% by weight. A further example of the content ratio of component (C) is 90 to 97% by weight.
(D)分岐鎖アミノ酸
本発明の経口組成物は、(D)成分としてバリン、ロイシン、及びイソロイシンからなる群より選択される分岐鎖アミノ酸を含む。(D)成分は、上記(A)成分、(B)成分及び(C)成分と共に組み合わされることによって、上記(A)成分~(C)成分の組み合わせにより奏される持久力向上効果を、より一層向上させることができる。
(D) Branched Chain Amino Acid The oral composition of the present invention contains a branched chain amino acid selected from the group consisting of valine, leucine, and isoleucine as component (D). By combining component (D) with component (A), component (B), and component (C), component (D) further enhances the endurance improvement effect produced by the combination of component (A) to component (C). This can be further improved.
これらの分岐鎖アミノ酸は、食品添加物、食品素材などとして市販されており、本発明の口腔用組成物においては、市販の分岐鎖アミノ酸をいずれも利用することができる。 These branched chain amino acids are commercially available as food additives, food materials, etc., and any commercially available branched chain amino acids can be used in the oral composition of the present invention.
(D)成分は、L-体、D-体およびDL-体のいずれであってもよいが、好ましくはL-体である。 Component (D) may be any of L-form, D-form and DL-form, but preferably L-form.
(D)成分としては、ロイシン、イソロイシン及びバリンの中から1種を単独で用いてもよいし、2種以上を組み合わせて用いてもよい。好ましくは、2種以上の組み合わせ、最も好ましくは、3種すべての組み合わせが挙げられる。 As component (D), one type from leucine, isoleucine and valine may be used alone, or two or more types may be used in combination. Preferably, a combination of two or more types, most preferably a combination of all three types is included.
ロイシン:イソロイシン:バリンの重量比としては、例えば2:1:1~8:1:2、好ましくは2:1:1~4:1:2、より好ましくは2:1:1~2:1:2が挙げられる。 The weight ratio of leucine:isoleucine:valine is, for example, 2:1:1 to 8:1:2, preferably 2:1:1 to 4:1:2, more preferably 2:1:1 to 2:1. :2 is mentioned.
本発明の経口組成物において、(A)~(D)成分の総量100重量%に対する(D)成分の含有比率については、付与すべき効能に応じ適宜設定すればよく、特に限定されないが、乾燥重量換算で、例えば、7~95重量%が挙げられる。より好ましい持久力向上効果を得る観点から、(D)成分の含有比率としては、好ましくは7~93重量%、より好ましくは8~91重量%、さらに好ましくは40~91重量%、一層好ましくは60~91重量%、より一層好ましくは65~91重量%、特に好ましくは70~91重量%、最も好ましくは75~91重量%が挙げられる。また、(C)成分の含有比率のさらなる例としては、75~85重量%が挙げられる。
が挙げられる。
In the oral composition of the present invention, the content ratio of component (D) to 100% by weight of the total amount of components (A) to (D) may be appropriately set depending on the efficacy to be imparted, and is not particularly limited. In terms of weight, for example, 7 to 95% by weight. From the viewpoint of obtaining a more preferable endurance improvement effect, the content ratio of component (D) is preferably 7 to 93% by weight, more preferably 8 to 91% by weight, still more preferably 40 to 91% by weight, and even more preferably 60 to 91% by weight, even more preferably 65 to 91% by weight, particularly preferably 70 to 91% by weight, and most preferably 75 to 91% by weight. A further example of the content ratio of component (C) is 75 to 85% by weight.
can be mentioned.
本発明の経口組成物において、(A)~(C)成分の総量100重量%に対する(D)成分の含有比率については、付与すべき効能に応じ適宜設定すればよく、特に限定されないが、乾燥重量換算で、例えば、7~1400重量%が挙げられる。より好ましい持久力向上効果を得る観点から、(C)成分の含有比率としては、好ましくは9~1400重量%、より好ましくは28~1400重量%が挙げられる。また、(D)成分の含有比率の他の例としては、75~1400重量%、好ましくは90~1400重量%、さらに好ましくは200~500重量%、一層好ましくは300~500重量%、より一層好ましくは350~500重量%が挙げられる。 In the oral composition of the present invention, the content ratio of component (D) to 100% by weight of the total amount of components (A) to (C) may be appropriately set depending on the efficacy to be imparted, and is not particularly limited. In terms of weight, for example, 7 to 1400% by weight. From the viewpoint of obtaining a more preferable endurance-improving effect, the content ratio of component (C) is preferably 9 to 1400% by weight, more preferably 28 to 1400% by weight. Other examples of the content ratio of component (D) include 75 to 1400% by weight, preferably 90 to 1400% by weight, more preferably 200 to 500% by weight, even more preferably 300 to 500% by weight, and even more preferably Preferably, the amount is 350 to 500% by weight.
その他の成分
本発明の経口組成物は、前記(A)~(C)成分又は前記(A)~(D)成分の他に、必要に応じて、他の栄養成分や薬理成分を含有していてもよい。このような栄養成分や薬理成分としては、飲食品や医薬品に使用可能なものであれば特に制限されないが、例えば、ビタミンB1、ビタミンB2、ビタミンB6、ビタミンB12、ビタミンC、ビタミンA、ビタミンD、ビタミンE、ビタミンK、ナイアシン、パントテン酸、葉酸、ビオチン、リコペン等のビタミン類;塩酸ベタイン、塩化カルニチン、塩化ベタネコール等の健胃剤;カルシウム、イオウ、マグネシウム、亜鉛、セレン、鉄等のミネラル類;大豆タンパク、卵白粉末、乳清タンパク等のタンパク質;グリシン、アラニン、シスチン、フェニルアラニン、タウリン、トリプトファン等の、上記(C)成分及び(D)成分以外のアミノ酸;リノール酸、γ-リノレン酸、α-リノレン酸、ドコサヘキサエン酸、エイコサペンタエン酸等の脂肪酸類;カラメル色素、クチナシ色素、アントシアニン色素、アナトー色素、パプリカ色素、紅花色素、紅麹色素、フラボノイド色素、コチニール色素、アマランス、エリスロシン、アルラレッドAC、ニューコクシン、フロキシン、ローズベンガル、アシッドレッド、タートラジン、サンセットイエローFCF、ファストグリーンFCF、ブリリアントブルーFCF、インジゴカルミン等の色素;各種フルーツのフレーバーやエッセンス等の香料;クエン酸及びその塩、リンゴ酸及びその塩、酒石酸及びその塩、酢酸及びその塩、乳酸及びその塩、食塩、グルタミン酸及びその塩、みりん、食酢、天然果汁、上記(A)成分及び(B)成分以外の植物抽出エキス、果実・海産物等の裁断物又は粉末化物等の調味剤;アガリクス、シイタケエキス、レイシ、ヤマブシタケ等のキノコ類又はそのエキス;食物繊維、ローヤルゼリー、プロポリス、ハチミツ、コンドロイチン硫酸、グルコサミン、セラミド、ヒアルロン酸等のその他機能性素材等が挙げられる。これらの添加成分は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの添加成分の含有量については、使用する添加成分の種類や経口組成物の用途等に応じて適宜設定される。
Other Components In addition to the components (A) to (C) or the components (A) to (D), the oral composition of the present invention may contain other nutritional components or pharmacological components as necessary. It's okay. Such nutritional ingredients and pharmacological ingredients are not particularly limited as long as they can be used in foods and drinks and medicines, but include, for example, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin A, and vitamin D. , vitamins such as vitamin E, vitamin K, niacin, pantothenic acid, folic acid, biotin, and lycopene; stomachic agents such as betaine hydrochloride, carnitine chloride, and bethanechol chloride; minerals such as calcium, sulfur, magnesium, zinc, selenium, and iron; Proteins such as soybean protein, egg white powder, and whey protein; Amino acids other than the above components (C) and (D), such as glycine, alanine, cystine, phenylalanine, taurine, and tryptophan; linoleic acid, γ-linolenic acid, α -Fatty acids such as linolenic acid, docosahexaenoic acid, and eicosapentaenoic acid; caramel pigment, gardenia pigment, anthocyanin pigment, annatto pigment, paprika pigment, safflower pigment, red yeast rice pigment, flavonoid pigment, cochineal pigment, amaranth, erythrosin, allura red AC, Pigments such as new coccine, phloxine, rose bengal, acid red, tartrazine, sunset yellow FCF, fast green FCF, brilliant blue FCF, indigo carmine; fragrances such as various fruit flavors and essences; citric acid and its salts, apple Acids and salts thereof, tartaric acid and salts thereof, acetic acid and salts thereof, lactic acid and salts thereof, common salt, glutamic acid and salts thereof, mirin, vinegar, natural fruit juice, plant extracts other than the above components (A) and (B), Seasonings such as cut or powdered fruits and marine products; Mushrooms such as agaricus, shiitake extract, reishi, Yamabushitake, etc. or their extracts; dietary fiber, royal jelly, propolis, honey, chondroitin sulfate, glucosamine, ceramide, hyaluronic acid, etc. and other functional materials. These additive components may be used alone or in combination of two or more. Further, the content of these additive components is appropriately set depending on the type of additive components used, the intended use of the oral composition, and the like.
更に、本発明の経口組成物は、所望の製剤形態に調製するために、必要に応じて、基剤や添加剤等が含まれていてもよい。このような基剤及び添加剤としては、食品や医薬品に使用可能なものであれば特に制限されないが、例えば、水、油脂類、ロウ類、炭化水素類、脂肪酸類、高級アルコール類、エステル類、水溶性高分子、界面活性剤、金属石鹸、低級アルコール類、多価アルコール、pH調整剤、緩衝剤、酸化防止剤、紫外線防止剤、防腐剤、香料、粉体、増粘剤、色素、キレート剤等が挙げられる。これらの添加成分は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの基剤や添加剤の含有量については、使用する添加成分の種類や経口組成物の用途等に応じて適宜設定される。 Furthermore, the oral composition of the present invention may contain a base, additives, etc., as necessary, in order to prepare it into a desired dosage form. Such bases and additives are not particularly limited as long as they can be used in foods and medicines, but include, for example, water, oils and fats, waxes, hydrocarbons, fatty acids, higher alcohols, and esters. , water-soluble polymers, surfactants, metal soaps, lower alcohols, polyhydric alcohols, pH adjusters, buffers, antioxidants, ultraviolet inhibitors, preservatives, fragrances, powders, thickeners, pigments, Examples include chelating agents. These additive components may be used alone or in combination of two or more. Further, the contents of these bases and additives are appropriately set depending on the type of additive components used, the intended use of the oral composition, and the like.
製造方法
本発明細胞内の抗酸化機能亢進剤の製造方法は、上記の前記(A)~(C)成分又は前記(A)~(D)成分と、必要に応じて配合されるその他の成分とを用いて、各種製剤形態及び性状、並びに使用目的に応じ、従来公知の通常の製剤手順に従えばよい。
Manufacturing method The method for manufacturing the intracellular antioxidant function enhancer of the present invention includes the above-mentioned components (A) to (C) or components (A) to (D), and other components blended as necessary. Conventionally known conventional formulation procedures may be followed depending on the various formulation forms and properties, as well as the purpose of use.
剤型・製剤形態
本発明の経口組成物の剤型については、経口摂取又は経口投与が可能であることを限度として特に制限されず、固体状、半固体状、又は液体状のいずれであってもよく、該経口組成物の種類や用途に応じて適宜設定すればよい。
Dosage form/Formulation The dosage form of the oral composition of the present invention is not particularly limited as long as it can be taken orally administered, and may be solid, semi-solid, or liquid. It may be set as appropriate depending on the type and use of the oral composition.
本発明の経口組成物の製剤形態については、経口摂取又は経口投与が可能であることを限度として特に制限されないが、具体的には、飲食品及び内服用医薬品が挙げられ、好ましくは飲食品が挙げられる。 The formulation form of the oral composition of the present invention is not particularly limited as long as it can be ingested or administered orally, but specific examples thereof include food and drink products and internal medicines, preferably food and drink products. Can be mentioned.
本発明の経口組成物を飲食品の製剤形態にする場合、前記(A)~(C)成分又は前記(A)~(D)成分を、そのまま又は他の食品素材や添加成分と組み合わせて所望の形態に調製すればよい。このような飲食品としては、一般の飲食品の他、特定保健用食品、栄養補助食品、機能性表示食品、病者用食品等が挙げられる。これらの飲食品の形態として、特に制限されないが、具体的にはカプセル剤(ソフトカプセル剤、ハードカプセル剤)、錠剤、顆粒剤、散剤、ゼリー剤等のサプリメント;栄養ドリンク、果汁飲料、炭酸飲料、乳酸飲料等の飲料;団子、アイス、シャーベット、グミ、キャンディー等の嗜好品等が例示される。これらの飲食品の中でも、好ましくはサプリメント、より好ましくはカプセル剤、錠剤、顆粒剤、散剤が挙げられる。持久力の向上効果をより良好に得る観点から、更に好ましくは顆粒剤、散剤、特に好ましくは顆粒剤が挙げられる。 When the oral composition of the present invention is made into a food or drink formulation, the components (A) to (C) or the components (A) to (D) can be used as is or in combination with other food materials or additive components as desired. It may be prepared in the following form. Examples of such foods and drinks include general foods and drinks, as well as foods for specified health uses, nutritional supplements, foods with functional claims, foods for the sick, and the like. The forms of these foods and drinks are not particularly limited, but specifically include supplements such as capsules (soft capsules, hard capsules), tablets, granules, powders, and jelly; energy drinks, fruit juice drinks, carbonated drinks, and lactic acid. Beverages such as beverages; luxury goods such as dumplings, ice cream, sherbet, gummies, and candies are exemplified. Among these foods and beverages, supplements are preferred, and capsules, tablets, granules, and powders are more preferred. From the viewpoint of better obtaining the effect of improving endurance, granules and powders are more preferred, and granules are particularly preferred.
本発明の経口組成物を内服用の医薬品の製剤形態にする場合、前記(A)~(C)成分又は前記(A)~(D)成分を、そのまま又は他の添加成分と組み合わせて所望の形態に調製すればよい。このような内服用の医薬品としては、具体的には、カプセル剤(ソフトカプセル剤、ハードカプセル剤)、錠剤、顆粒剤、散剤、ゼリー剤、シロップ剤等が挙げられる。 When the oral composition of the present invention is made into a pharmaceutical formulation for internal use, the components (A) to (C) or the components (A) to (D) can be used as is or in combination with other additive components to obtain the desired dosage. It may be prepared in any form. Specific examples of such medicines for internal use include capsules (soft capsules, hard capsules), tablets, granules, powders, jellies, syrups, and the like.
用途
本発明の経口組成物は、優れた持久力向上効果を有する。従って、本発明の経口組成物は、持久力向上の用途で用いることができ、特に全身持久力向上の用途で用いることができる。全身持久力は、心肺持久力ともいい、全身及び心肺を長時間動かし続けられる力をいう。全身持久力は、主に内臓の力を必要とする。全身持久力の評価は、初期クーパーテストによって行うことができる。初期クーパーテストは、被験者に12分間陸上トラックをランニングさせ、12分の時点での総移動距離を測り、走行距離から被験者それぞれの最大酸素摂取量(VO2max)を概算予測し、VO2maxと持久力との相対関係に基づいて持久力を評価するというものである。
Uses The oral composition of the present invention has an excellent effect of improving endurance. Therefore, the oral composition of the present invention can be used for improving endurance, particularly for improving whole body endurance. Whole body endurance, also known as cardiopulmonary endurance, refers to the ability to keep the whole body and heart and lungs moving for a long period of time. Whole body endurance primarily requires internal strength. Assessment of whole body endurance can be performed by an initial Cooper test. The initial Cooper test had subjects run on a track for 12 minutes, measured the total distance traveled at the 12 minute mark, estimated each subject's maximum oxygen uptake (VO2max) from the distance traveled, and calculated the relationship between VO2max and endurance. The idea is to evaluate endurance based on the relative relationship between
このような持久力を要する運動としては、家事、歩き仕事、ウォーキング等の日常的な運動のみならず、マラソン、水泳、テニス、サッカー、バスケットボール、ラグビー、スキー、トライアスロン、ロードレース等の持久系スポーツが挙げられる。このような運動において持久力を向上させることによって、身体能力を向上させ、それによって運動のパフォーマンスを向上させることができる。例えば持久系スポーツにおいては、走行時のスタミナが向上するため、走行距離の向上、長距離走行タイムの短縮、走行時における身体の良好な動作等のスポーツパフォーマンスの向上が期待できる。従って、本発明の経口組成物は、好ましくは、スポーツパフォーマンスの向上の用途に用いることができる。 Exercises that require endurance include not only daily activities such as housework, walking work, and walking, but also endurance sports such as marathons, swimming, tennis, soccer, basketball, rugby, skiing, triathlons, and road races. can be mentioned. By improving endurance in such exercises, one can improve physical capacity and thereby improve athletic performance. For example, in endurance sports, improving stamina during running can be expected to improve sports performance, such as increasing running distance, shortening long-distance running time, and improving body movement during running. Therefore, the oral composition of the present invention can be preferably used for improving sports performance.
また、本発明の経口組成物は、筋肉不快感の低減又は予防等の用途で用いることもできる。筋肉不快感としては、例えば、筋持久力が低下している状態が挙げられる。筋持久力が不足している場合の状態としては、運動開始時、運動中、運動終了時における筋肉痛(急性筋肉痛)、筋痙攣等の筋肉不快感が挙げられる。ここで、筋持久力も、上述の全身持久力と同様に持久力の一形態であり、一部分の筋肉を長時間動かし続けられる力をいう。筋持久力の向上は、例えば、上記のスポーツパフォーマンスの向上のうち、走行時における身体の良好な動作の向上にも寄与する。つまり、本発明の経口組成物は、筋持久力の向上を伴って筋肉不快感を総合的に低減又は予防する用途で用いることができる。 Moreover, the oral composition of the present invention can also be used for purposes such as reducing or preventing muscle discomfort. Examples of muscle discomfort include a state where muscular endurance is decreased. Conditions when muscle endurance is insufficient include muscle discomfort such as muscle pain (acute muscle pain) and muscle spasms at the start of exercise, during exercise, and at the end of exercise. Here, muscular endurance is also a form of endurance, similar to the above-mentioned whole body endurance, and refers to the power that allows one muscle to continue moving for a long period of time. Improving muscular endurance also contributes to, for example, improving the body's good movement during running, among the above-mentioned improvements in sports performance. In other words, the oral composition of the present invention can be used to improve muscle endurance and comprehensively reduce or prevent muscle discomfort.
本発明の経口組成物を投与する対象としては、持久力向上を求める対象であればよく、老若男女を問わず、ヒト以外の哺乳動物であってもよい。好ましくは、ヒトが挙げられる。また、本発明の経口組成物を投与する対象としては、スポーツ以外で日常的に体を動かす人であってもよいし、アスリートであってもよい。好ましくは、アスリートが挙げられる。また、アスリートの中でも、持久力の向上効果をより良好に得る観点から、アマチュアアスリートが好ましい。 The subject to whom the oral composition of the present invention is administered may be any subject seeking to improve endurance, and may be a mammal other than humans, regardless of age or sex. Preferably, humans are mentioned. Furthermore, subjects to whom the oral composition of the present invention is administered may be people who regularly exercise their bodies other than sports, or may be athletes. Preferably, athletes are mentioned. Moreover, among athletes, amateur athletes are preferable from the viewpoint of better obtaining the effect of improving endurance.
用量・用法
本発明の経口組成物の摂取又は服用量については、特に限定されず、前記経口組成物の製剤形態、用途、(A)成分、(B)成分、(C)成分、(D)成分の含有量等に応じて適宜設定されるが、例えば、成人の場合、1日あたり500~13,500mg、好ましくは1000~13,500mg、より好ましくは1,200~13,500mg、さらに好ましくは1,700~13,500mg、一層好ましくは3,000~9,000mgが挙げられる。1日当たりの摂取又は服用回数としては、例えば1~5回、好ましくは2~4回が挙げられる。
Dose/Usage There are no particular limitations on the intake or dosage of the oral composition of the present invention, and there are no particular limitations on the dosage form, use, (A) component, (B) component, (C) component, (D) of the oral composition. It is set appropriately depending on the content of the ingredient, etc., but for example, for adults, it is 500 to 13,500 mg per day, preferably 1000 to 13,500 mg, more preferably 1,200 to 13,500 mg, and even more preferably is preferably 1,700 to 13,500 mg, more preferably 3,000 to 9,000 mg. The number of times of intake or administration per day is, for example, 1 to 5 times, preferably 2 to 4 times.
本発明の経口組成物を摂取するタイミングとしては特に限定されず、食前、食間、食後、運動前、運動後のいずれであってもよい。持久力の向上効果をより良好に得る観点から、運動前の摂取が好ましい。また、本発明の経口組成物が、カプセル剤、錠剤、顆粒剤、粉剤、ゼリー剤等の固体である場合は、そのままで、又は水と共に摂取又は服用することができる。また、本発明の経口組成物が、顆粒剤又は粉剤である場合、水に溶解又は分散させてスポーツドリンクとして調製したものを飲用することで摂取又は服用することもできる。 The timing of ingesting the oral composition of the present invention is not particularly limited, and may be before meals, between meals, after meals, before exercise, or after exercise. From the viewpoint of better obtaining the effect of improving endurance, it is preferable to take it before exercise. Furthermore, when the oral composition of the present invention is in the form of a solid such as a capsule, tablet, granule, powder, or jelly, it can be ingested or taken as is or with water. Furthermore, when the oral composition of the present invention is in the form of granules or powder, it can also be ingested or administered by dissolving or dispersing it in water and preparing it as a sports drink.
持久力の向上効果をより良好に得るために、本発明の経口組成物を継続的に摂取することが好ましい。継続期間としては、例えば3週間以上が挙げられる。また、持久力の向上効果をより良好に得るために、摂取期間中も運動を行うことが好ましい。 In order to better obtain the effect of improving endurance, it is preferable to continuously ingest the oral composition of the present invention. The duration may be, for example, 3 weeks or more. Furthermore, in order to better obtain the effect of improving endurance, it is preferable to exercise during the intake period as well.
以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 EXAMPLES The present invention will be explained in more detail with reference to Examples below, but the present invention is not limited thereto.
試験例
経口組成物の調製
表1の組成を有する経口組成物(「フィットネスドリンク」(FD))を調製した。経口組成物は、表1の組成の粉末組成物を水に溶かして全量300mLとして用いた。表1に示す量は、1日の摂取量である。表1で用いられた各成分の詳細は以下の通りである。・松樹皮抽出物:フランス松樹皮抽出物Pycnogenol(登録商標)、濃縮率1000倍
・ヨーロッパナラ抽出物:Robuvit(登録商標)、濃縮率50倍
・アルギニン:L-アルギニン
・ロイシン:L-ロイシン
・バリン:L-バリン
・イソロイシン:L-イソロイシン
Test example
Preparation of Oral Composition An oral composition ("Fitness Drink" (FD)) having the composition in Table 1 was prepared. The oral composition was prepared by dissolving a powder composition having the composition shown in Table 1 in water to make a total volume of 300 mL. The amounts shown in Table 1 are daily intakes. Details of each component used in Table 1 are as follows.・Pine bark extract: French pine bark extract Pycnogenol (registered trademark), concentration rate 1000 times ・European oak extract: Robuvit (registered trademark), concentration rate 50 times ・Arginine: L-arginine ・Leucine: L-leucine Valine: L-valine Isoleucine: L-isoleucine
試験対象の選定
試験対象は以下の通りである。
・年齢30~45歳
・プロでないアスリート
・FD摂取前の2週間以内に、スポーツドリンク、エネルギー製品、トレーニング用製品、ビタミン製品、薬物について非摂取である者
・FD摂取前の3カ月以内における心電図が正常であり;FD摂取前の3年間にいかなる種類の臨床的問題もなく;医学的処置または薬物処置を必要とするいかなる疾患も有さず;糖尿病患者でなく;過体重でない健常者
Selection of test targets The test targets are as follows.
・Age 30-45 years old ・Non-professional athletes ・Those who have not consumed sports drinks, energy products, training products, vitamin products, or drugs within 2 weeks before taking FD ・Electrocardiogram within 3 months before taking FD normal; without any clinical problems of any kind in the 3 years prior to FD intake; without any disease requiring medical or drug treatment; not diabetic; healthy individuals who are not overweight.
試験方法
(試験環境)
試験は、平均気温が18~22℃である4~6月の間に行った。
(第1のクーパーテスト:摂取前の走行距離測定)
FDの摂取前に、初期クーパーテスト(以下、単にクーパーテストと記載する)を行った。クーパーテストでは、平坦な走路での12分間における走行距離を測定した。
(FD摂取方法)
3週間毎日、表1に記載のFDを摂取させた。具体的には、表1に記載の量を1日の用量として、1日に4回(8時、12時、18時、20時)に分けて飲用させた。
(対照)
FDを摂取しない対照には、水と電解質溶液(Cool Blue、Gatorade)とを同体積の割合で含む、FDと同量の対照飲料を飲用させた。
(群分け)
クーパーテストでの結果の測定値の変動(標準状態での平均の個体内変動>3%、及び個体間変動<4%)を考慮し、試験群は、1種類のFDにつき、30名の被験者で構成した。対照群は、30名の対照で構成した。1群につき、25%以上の女性被験者を含む。
(トレーニング)
すべての被験者は、適切な専門管理の下、アスレチック用品(特に、シューズおよび服装)を使用してトレーニングを行った。FD又は対照飲料の摂取期間中、毎日、1日当たり2回トレーニングを行った。具体的には、10時と12時の間と、18時と20時との間にトレーニングを行った。1回のトレーニングには30分を要し、その内訳としては、15分間のウォーミングアップ及びストレッチング、オリンピック標準陸上競技場(Stadio Adriatico、Pescara)でのランニングであるクーパーテスト(CT)1回、リラックス、及び5分間の無理のないランニングである。
(第2のクーパーテスト:3週間摂取後の走行距離測定)
3週間のトレーニング期間終了時に、クーパーテストを行った。
Test method (test environment)
The tests were conducted between April and June, when the average temperature is 18-22°C.
(First Cooper test: mileage measurement before intake)
Before ingesting FD, an initial Cooper test (hereinafter simply referred to as Cooper test) was conducted. In the Cooper test, the distance traveled in 12 minutes on a flat road was measured.
(FD intake method)
The animals were allowed to ingest the FD listed in Table 1 every day for 3 weeks. Specifically, the daily dose was the amount listed in Table 1, which was divided into four doses per day (8:00, 12:00, 18:00, and 20:00).
(control)
Controls not taking FD were allowed to drink the same amount of a control drink as the FD, which contained equal volumes of water and an electrolyte solution (Cool Blue, Gatorade).
(Group division)
Considering the variation in the measured values of the Cooper test results (average intra-individual variation > 3% and inter-individual variation < 4% under standard conditions), the test group consisted of 30 subjects for each type of FD. It was composed of The control group consisted of 30 controls. Include 25% or more female subjects per group.
(training)
All subjects trained using athletic equipment (particularly shoes and clothing) under appropriate professional supervision. Training was performed twice per day every day during the intake period of FD or control beverage. Specifically, training was conducted between 10:00 and 12:00 and between 18:00 and 20:00. Each training session takes 30 minutes, including 15 minutes of warm-up and stretching, one run of the Cooper Test (CT) at the Olympic standard athletics stadium (Stadio Adriatico, Pescara), and relaxation. , and a 5-minute effortless run.
(Second Cooper test: mileage measurement after 3 weeks of intake)
At the end of the 3-week training period, a Cooper test was performed.
評価方法
(評価項目1-全身持久力)
クーパーテストにおいては、12分間の走行距離(d12)から最大酸素摂取量VO2maxを予測することができる。最大酸素摂取量VO2max(ml/分/kg)は、次の式:
VO2max=(d12-505)/45
で表され、12分間の走行距離d12と相関することが知られている。つまり、走行距離と持久力レベルとは相関しており、具体的には、走行距離が20%増加すると持久力レベルが向上したことが認められる。これに基づいて、FD摂取前に比べてFD3週間摂取後における走行距離が20%以上増加した被験者の人数を、評価項目1の評点とした。結果を表1に示す。
Evaluation method (Evaluation item 1-Whole body endurance)
In the Cooper test, the maximum oxygen intake amount VO2max can be predicted from the 12-minute running distance (d12). The maximum oxygen uptake VO2max (ml/min/kg) is calculated by the following formula:
VO2max=(d12-505)/45
It is known that it is correlated with the running distance d12 for 12 minutes. In other words, there is a correlation between running distance and endurance level, and specifically, it is recognized that when running distance increases by 20%, endurance level improves. Based on this, the number of subjects whose mileage increased by 20% or more after taking FD for 3 weeks compared to before taking FD was determined as the score for evaluation item 1. The results are shown in Table 1.
(評価項目2-筋肉不快感)
運動開始時の筋肉痛、運動中及び運動終了時の筋肉痛、及び筋痙攣を含む筋肉不快感の程度について、それぞれアナログスケールラインを用いて0点~5点(5点が最も筋肉不快感が大きい)でスコア化した。運動開始時の筋肉痛、運動中及び運動終了時の筋肉痛、及び筋痙攣は、いずれも筋持久力が低下した状態であり、これらの状態の改善(つまり筋持久力の向上)効果の寄与によって、総合的に筋肉不快感の低減効果が得られる。FD摂取前に比べてFD3週間摂取後における総スコアが50%以上減少した人数を、評価項目2の評点とした。結果を表1に示す。
(Evaluation item 2 - muscle discomfort)
The level of muscle pain at the start of exercise, muscle pain during and at the end of exercise, and muscle discomfort, including muscle spasms, was scored from 0 to 5 using an analog scale line (5 points being the most muscular discomfort). (larger)). Muscle pain at the start of exercise, muscle pain during and at the end of exercise, and muscle spasms are all conditions in which muscular endurance is decreased, and the effect of improving these conditions (in other words, improving muscular endurance) may contribute. This provides a comprehensive effect of reducing muscle discomfort. The number of people whose total score decreased by 50% or more after taking FD for 3 weeks compared to before taking FD was defined as the score for evaluation item 2. The results are shown in Table 1.
表1から明らかなとおり、松樹皮抽出物、ヨーロッパナラ抽出物、アルギニン、及び分岐鎖アミノ酸(ロイシン、バリン、イソロイシンのうちの少なくともいずれか)を単独で含む経口組成物(比較例1~6)や、アルギニン及び分岐鎖アミノ酸を組み合わせた口腔組成物(比較例7)では持久力の効果的な向上は認められなかったが、松樹皮抽出物、ヨーロッパナラ抽出物及びアルギニンを含む経口組成物(参考例1)と、松樹皮抽出物、ヨーロッパナラ抽出物及びアルギニンに加えて、分岐鎖アミノ酸(ロイシン、バリン、イソロイシン)を含む経口組成物(実施例1,2)によると、優れた持久力の向上効果が認められた。さらに、分岐鎖アミノ酸の有無を除いて同じ組成の実施例2と参考例との対比から、松樹皮抽出物、ヨーロッパナラ抽出物及びアルギニンに、分岐鎖アミノ酸を加えることで、持久力の向上効果がより一層向上することが認められた。なお、評価項目2において用いた3週間後のスコアについて、試験群と対照群とを対比すると、統計的有意差(p<0.05)をもって、筋肉不快感が低減したことも認められた。 As is clear from Table 1, oral compositions containing pine bark extract, European oak extract, arginine, and branched chain amino acids (at least one of leucine, valine, and isoleucine) alone (Comparative Examples 1 to 6) An oral composition containing pine bark extract, European oak extract, and arginine (Comparative Example 7) was not found to effectively improve endurance. According to Reference Example 1) and oral compositions containing branched chain amino acids (leucine, valine, isoleucine) in addition to pine bark extract, European oak extract, and arginine (Examples 1 and 2), excellent stamina was achieved. An improvement effect was observed. Furthermore, from a comparison between Example 2 and Reference Example, which have the same composition except for the presence or absence of branched chain amino acids, it was found that the addition of branched chain amino acids to pine bark extract, European oak extract, and arginine improved endurance. It was recognized that the results improved even further. In addition, when comparing the test group and the control group with respect to the score after 3 weeks used in evaluation item 2, it was also observed that muscle discomfort was reduced with a statistically significant difference (p<0.05).
処方例
処方例1~27に示す散剤の経口組成物、及び処方例28~30に示す顆粒剤の経口組成物を調製した。いずれの経口組成物も、経口摂取により全身持久力が向上し筋肉不快感が低減した。
Formulation Examples Powder oral compositions shown in Formulation Examples 1 to 27 and granule oral compositions shown in Formulation Examples 28 to 30 were prepared. Oral intake of all oral compositions improved whole body endurance and reduced muscle discomfort.
Claims (7)
前記(A)成分~前記(D)成分の総量100重量%に対する前記(A)成分の含有量が0.9~3重量%である、経口組成物。 (A) a plant extract containing proanthocyanidins, (B) a Fagaceae plant extract, (C) an arginine source selected from the group consisting of arginine, citrulline, ornithine, aspartic acid, aspartate and/or aspartate dipeptide , and (D) a branched chain amino acid selected from the group consisting of valine, leucine, and isoleucine,
An oral composition, wherein the content of component (A) is 0.9 to 3% by weight based on 100% by weight of the total amount of components (A) to (D).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023201066A JP2024015087A (en) | 2019-03-19 | 2023-11-28 | Oral composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019051599A JP7460327B2 (en) | 2019-03-19 | 2019-03-19 | Oral Compositions |
JP2023201066A JP2024015087A (en) | 2019-03-19 | 2023-11-28 | Oral composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019051599A Division JP7460327B2 (en) | 2019-03-19 | 2019-03-19 | Oral Compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2024015087A true JP2024015087A (en) | 2024-02-01 |
Family
ID=72556336
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019051599A Active JP7460327B2 (en) | 2019-03-19 | 2019-03-19 | Oral Compositions |
JP2023201066A Pending JP2024015087A (en) | 2019-03-19 | 2023-11-28 | Oral composition |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019051599A Active JP7460327B2 (en) | 2019-03-19 | 2019-03-19 | Oral Compositions |
Country Status (1)
Country | Link |
---|---|
JP (2) | JP7460327B2 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005097273A (en) * | 2003-08-19 | 2005-04-14 | Toyo Shinyaku:Kk | Athletic ability-enhancing composition |
WO2011161655A1 (en) * | 2010-06-25 | 2011-12-29 | Horphag Research (Ip) Pre Ltd | Composition for improving sexual wellness |
GB201413228D0 (en) * | 2014-07-25 | 2014-09-10 | Nugerontix Ltd | Polyphenol compositions |
-
2019
- 2019-03-19 JP JP2019051599A patent/JP7460327B2/en active Active
-
2023
- 2023-11-28 JP JP2023201066A patent/JP2024015087A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7460327B2 (en) | 2024-04-02 |
JP2020150826A (en) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3907964B2 (en) | Mental fatigue reducing composition, concentration maintenance enhancing composition and mental vitality maintenance enhancing composition | |
AU2019200802B2 (en) | Synergistic dietary supplement compositions for enhancing physical performance | |
JP4739161B2 (en) | Endurance improver | |
TW202103574A (en) | Sports and nutritional supplement formulations | |
US20130344179A1 (en) | Anti-fatigue composition | |
TW200913988A (en) | Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient | |
EP3115047B1 (en) | Debility preventative | |
CA2731282C (en) | Anti-fatigue composition | |
KR20240004452A (en) | 1-Methylxanthine-based bioactive compositions and methods of using the same | |
JP7460327B2 (en) | Oral Compositions | |
WO2023097091A1 (en) | Paraxanthine-based compositions for enhancing muscle function, nitric oxide signaling, and/or muscle glycogen levels | |
KR20130119424A (en) | Ingredients derived from sphaeranthus indicus | |
EP3209147A1 (en) | Composition comprising plant proteins and use for preventing metabolic and cardiovascular pathological conditions associated with cardiometabolic risk in particular with hyperglycaemia | |
US20190070139A1 (en) | Agent for improving physical fitness | |
JP7418170B2 (en) | Oral composition | |
US10542989B2 (en) | Synergistic dietary supplement compositions for enhancing physical performance and energy levels | |
JP7436166B2 (en) | Menopausal symptom improvement agent | |
JP2024002801A (en) | Oral composition | |
TW201300102A (en) | Use of jasmonate for improving skeletal muscle function | |
CN117979971A (en) | Bioactive compositions based on 1-methylxanthines and methods of use thereof | |
BRPI1100167A2 (en) | antifatigue composition | |
Myers | Bigger Muscles With Improved Blood Flow Bigger Muscles With Improved Blood Flow | |
JP2006096768A (en) | Brain fag-reducing composition, concentration-sustaining and enhancing composition, and mental activity-sustaining and enhancing composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231129 |